The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Betahistine dihydrochloride 8 mg Tablets

Azure Pharmaceuticals LtdPA22871/017/001

Main Information

Trade NameBetahistine dihydrochloride 8 mg Tablets
Active SubstancesBetahistine dihydrochloride
Dosage FormTablet
Licence HolderAzure Pharmaceuticals Ltd
Licence NumberPA22871/017/001

Group Information

ATC CodeN07CA01 betahistine


License statusAuthorised
Licence Issued21/01/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportPDF Version

Generics Information

Interchangeable ListBetahistine 8mg Tablets
Interchangeable List CodeIC0084-009-002
Interchangeable List DocumentPDF of Interchangeable List
« Back